FINWIRES · TerminalLIVE
FINWIRES
$PFE

$PFE

63 stories mentioning PFEUpdated 16d ago

Every FINWIRES story that references PFE, newest first.

What are analysts saying about PFE?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on PFE?

BioNTech Terminates Phase 2 Colorectal Cancer Clinical Trial; Shares Fall
US Markets

BioNTech Terminates Phase 2 Colorectal Cancer Clinical Trial; Shares Fall

BioNTech (BNTX) shares slumped Friday after the company said it is terminating a mid-stage clinical trial of an experimental treatment of colorectal cancer, following a new recommendation from the study's independent data safety monitoring board.The German drugmaker was studying autogene cevumeran, an investigational mRNA-based cancer immunotherapy product, as an adjuvant therapy for patients suffering from resected stage II or stage III colorectal cancer in a phase 2 trial. BioNTech was jointly developing the candidate with Genentech, a member of the Roche Group.The decision to terminate the trial came after its safety board recommended discontinuing patient treatment and ending the study, according to BioNTech. The independent board, which also oversees the trial's integrity, identified a "numerical imbalance" in overall survival between treatment arms in patients and indicated further continuation was not expected to change the efficacy outcome, the company said Friday."While this outcome is not what we had envisioned for mRNA as a monotherapy in colorectal cancer, it provides scientific insight into the challenges of treating immunotherapy-insensitive tumor types with immune-suppressive microenvironments and will help inform the further development of investigational mRNA cancer immunotherapies," BioNTech Co-Founder and Chief Medical Officer Ozlem Tureci said in a statement.BioNTech's Nasdaq-listed shares fell 7.8% in afternoon trade. The stock has gained 8% in value so far this year.In October, the trial crossed its futility boundary, but the safety board had identified that the trial's data wasn't adequately "mature" to make reliable conclusions regarding its efficacy and there was insufficient follow-up time to evaluate its primary endpoint. BioNTech decided to continue the study at the time with no objection from the board.The company said Friday intends to continue a separate phase 2 study evaluating autogene cevumeran in combination with checkpoint inhibition and chemotherapy for adjuvant pancreatic ductal adenocarcinoma, the most common and aggressive type of pancreatic cancer.Earlier this month, Moderna (MRNA) and Merck (MRK) said a late-stage trial of an experimental skin cancer treatment yielded positive topline results.On Thursday, BioNTech and Pfizer (PFE) said the US Food and Drug Administration approved the supplemental biologics license application for their 2026-2027 COVID-19 vaccine targeting the XFG variant.Price: $103.14, Change: $-8.26, Percent Change: -7.41%

$BNTX$MRK$MRNA$PFE
Sectors

Sector Update: Healthcare Stocks Climb Late Afternoon

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.8%.The iShares Biotechnology ETF (IBB) was up 1%.In corporate news, Haemonetics (HAE) shares jumped past 16% after the company said it entered into a supply agreement with CSL Plasma last week.Pfizer (PFE) was Smart Insider's stock pick of the week after Chief Executive and Chair Albert Bourla bought 38,000 shares for $1 million at $26.34 apiece on Aug. 12. Bourla, who has been with Pfizer since 1993 and has served as CEO since January 2020, increased his holding by 10% to $11.6 million with his first reported purchase, Smart Insider said in a Tuesday note. Pfizer shares rose 1.5%.Amylyx Pharmaceuticals (AMLX) shares surged 63% after the company said Tuesday its investigational post-bariatric hypoglycemia treatment Avexitide met its primary endpoint in a phase 3 trial.GE HealthCare (GEHC) has appointed William Grogan as chief financial officer, effective Sept. 14, the company said Tuesday. Grogan succeeds Jay Saccaro, who stepped down to pursue another opportunity outside the medical technology industry, the company said. GE HealthCare shares were up 0.6%.

$AMLX$GEHC$HAE$PFE
Sectors

Sector Update: Healthcare Stocks Rise Tuesday Afternoon

Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index rising 1.8% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.7%.The iShares Biotechnology ETF (IBB) was up 0.8%.In corporate news, Amylyx Pharmaceuticals (AMLX) shares surged nearly 55% after the company said Tuesday its investigational post-bariatric hypoglycemia treatment Avexitide met its primary endpoint in a phase 3 trial.Pfizer (PFE) was Smart Insider's stock pick of the week after Chief Executive and Chair Albert Bourla bought 38,000 shares for $1 million at $26.34 apiece on Aug. 12. Bourla, who has been with Pfizer since 1993 and has served as CEO since January 2020, increased his holding by 10% to $11.6 million with his first reported purchase, Smart Insider said in a Tuesday note. Pfizer shares rose 1.4%.GE HealthCare (GEHC) has appointed William Grogan as chief financial officer, effective Sept. 14, the company said Tuesday. Grogan succeeds Jay Saccaro, who stepped down to pursue another opportunity outside the medical technology industry, the company said. GE HealthCare shares were up 0.6%.

$AMLX$GEHC$PFE
Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index decreasing 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.5%.The iShares Biotechnology ETF (IBB) lost 0.5%.In corporate news, Luigi Mangione is expected to plead guilty to federal charges related to the killing of former UnitedHealth (UNH) executive Brian Thompson, according to his lawyer, multiple media outlets reported Friday. UnitedHealth shares were up 0.8%.Valneva (VALN) shares jumped 25% after the company and Pfizer (PFE) said the European Medicines Agency validated their marketing authorization application for their Lyme disease vaccine candidate, starting the regulatory review process. Pfizer shares were fractionally lower.Eton Pharmaceuticals (ETON) shares surged 41%. The company late Thursday reported Q2 adjusted earnings and revenue above market expectations and raised full-year 2026 sales guidance.Zentalis Pharmaceuticals (ZNTL) shares fell past 12% in Friday trading, a day after the company priced an offering of 23 million shares at $3.50 each, targeting about $80.5 million in gross proceeds.

$ETON$PFE$UNH$VALN$ZNTL
Wire

Sector Update: Healthcare Stocks Decline Friday Afternoon

Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index decreasing 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.6%.The iShares Biotechnology ETF (IBB) lost 0.6%.In corporate news, Luigi Mangione is expected to plead guilty to federal charges related to the killing of former UnitedHealth (UNH) executive Brian Thompson, according to his lawyer, multiple media outlets reported Friday. UnitedHealth shares were up 0.5%.Valneva (VALN) shares jumped 27% after the company and Pfizer (PFE) said the European Medicines Agency validated their marketing authorization application for their Lyme disease vaccine candidate, starting the regulatory review process. Pfizer shares were fractionally lower.Heartflow (HTFL) shares surged 33% after it posted a narrower Q2 non-GAAP loss, as revenue increased during the period, and raised its 2026 revenue outlook.

$HTFL$PFE$UNH$VALN
Sectors

Sector Update: Healthcare Stocks Flat to Lower Pre-Bell Friday

Healthcare stocks were flat to lower pre-bell Friday, with the iShares Biotechnology ETF (IBB) unchanged and the State Street Health Care Select Sector SPDR ETF (XLV) declining by 0.2%.Heartflow (HTFL) stock was up nearly 24% after the company posted a narrower Q2 non-GAAP loss, as revenue increased during the period, and raised its 2026 revenue outlook.Valneva (VALN) shares were up nearly 26% after the company and Pfizer (PFE) said the European Medicines Agency validated their marketing authorization application for their Lyme disease vaccine candidate, starting the regulatory review process. Pfizer stock was 0.1% lower premarket.Capricor Therapeutics (CAPR) shares were up more than 85% after the company said the US Food and Drug Administration is willing to review an amendment to its biologics license application for deramiocel, potentially shifting the drug's focus to upper-limb skeletal muscle function in Duchenne muscular dystrophy.

$CAPR$HTFL$IBB$PFE$VALN$XLV
S&P 500 Companies' Quarterly Earnings Growth Eases Amid Healthcare Drop, Oppenheimer Says
US Markets

S&P 500 Companies' Quarterly Earnings Growth Eases Amid Healthcare Drop, Oppenheimer Says

S&P 500 companies' quarterly earnings growth rate eased from a week ago amid a drop in the healthcare sector, though the results continue to be "strong" overall, Oppenheimer Asset Management said Monday.Some 89% of the companies in the benchmark equity index have reported results in the ongoing cycle, with earnings rising about 51% year over year, compared with 57% growth a week ago. Revenue growth eased to 14.6% from 14.8%, the report showed.The healthcare sector saw earnings fall 7.5% on an annual basis, compared with a 20% jump a week ago.In the sector, Merck (MRK) swung to a quarterly loss amid an acquisition charge, while Pfizer's (PFE) second-quarter adjusted earnings fell year over year last week.The remaining 10 S&P 500 sectors reported year-over-year profit growth, with energy up 147%. Consumer discretionary and communication services soared more than 110% each, Oppenheimer said Monday.Bottom-up estimates from FactSet put analysts' projected earnings growth at 24% prior to the start of the latest reporting season, according to the brokerage.In terms of sales, energy continued to lead the sectors with a 42% annual gain for the quarter, followed by technology's 27% advance."Continued strong results reported for (the second-quarter) earnings season, along with economic data that showed acceleration in services and manufacturing activity even as jobs declined in July, lent support for the (Federal Reserve) to remain 'on hold'," Oppenheimer Asset Management Chief Investment Strategist John Stoltzfus said in a note to clients."In addition to these solid reported results, a number of company managers in key sectors have provided positive forward guidance, suggesting that conditions are favorable for further improvement ahead," Stoltzfus wrote.Only 11 S&P 500 companies are scheduled to report results this week, including Cisco (CSCO), Applied Materials (AMAT), and Simon Property (SPG).Markets are pricing in a 50% probability that the Fed will leave its benchmark lending rate unchanged in September, with the remaining odds in the favor of a 25-basis-point increase, according to the CME FedWatch tool.Price: $130.65, Change: $+2.07, Percent Change: +1.61%

$AMAT$CSCO$MRK$PFE$SPG
Wire

Merck's Keytruda Gets Canadian Approval to Treat Muscle-Invasive Bladder Cancer

Merck (MRK) said Wednesday that Keytruda, in combination with enfortumab vedotin, has received Canadian approval for the treatment of muscle-invasive bladder cancer in adults who are ineligible for cisplatin-containing chemotherapy.The company said that the approval from Health Canada was based on results from a phase-3 trial, which was conducted in collaboration with Pfizer (PFE) and Astellas.Results from the trial showed that patients treated with neoadjuvant and adjuvant Keytruda in combination with enfortumab vedotin had statistically significant improvements in event-free survival and overall survival compared with radical cystectomy and pelvic lymph node dissection alone, the company said.Price: $130.02, Change: $+2.02, Percent Change: +1.58%

$MRK$PFE
Wire

Rothschild & Co Redburn Adjusts Pfizer Price Target to $25 From $24, Maintains Neutral Rating

Pfizer (PFE) has an average rating of hold and mean price target of $28.38, according to analysts polled by FactSet.Price: $25.46, Change: $+0.05, Percent Change: +0.19%

$PFE
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index down 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.3%.The iShares Biotechnology ETF (IBB) climbed 2%.In corporate news, AdaptHealth (AHCO) reported a Q2 loss Tuesday, with revenue below market expectations. The company also lowered its full-year 2026 sales guidance. Its shares fell 37%.AbbVie (ABBV) has commenced a $10 billion investment-grade bond sale to help finance its pending acquisition of Apogee Therapeutics (APGE), Bloomberg reported. The offering, which includes bonds maturing in two to 40 years, has drawn about $63 billion of peak demand, the report said. AbbVie shares were down 0.4%.BioNTech (BNTX) shares shed 0.5% after it reported a wider Q2 adjusted loss and lower revenue, and cut its 2026 revenue guidance.Merck (MRK) and Pfizer (PFE) raised their respective full-year sales outlooks on Tuesday, as both pharmaceutical giants logged better-than-expected sales for Q2. Merck shares rose 0.6%, and Pfizer added 1.5%.

$ABBV$AHCO$BNTX$MRK$PFE
Sectors

Sector Update: Healthcare Stocks Decline Tuesday Afternoon

Healthcare stocks were lower Tuesday afternoon, with the NYSE Healthcare Index down 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) easing 0.2%.The iShares Biotechnology ETF (IBB) climbed 1.7%.In corporate news, BioNTech (BNTX) shares fell nearly 1% after it reported a wider Q2 adjusted loss and lower revenue, and cut its 2026 revenue guidance.Merck (MRK) and Pfizer (PFE) raised their respective full-year sales outlooks on Tuesday, as both pharmaceutical giants logged better-than-expected sales for Q2. Merck shares rose 0.8%, and Pfizer added 1.6%.AbbVie's (ABBV) Allergan Aesthetics unit said Tuesday that the US Food and Drug Administration has accepted for review its supplemental biologics license application for BOTOX Cosmetic, or onabotulinumtoxinA for masseter muscle prominence. AbbVie shares were down 1%.

$ABBV$BNTX$MRK$PFE
Sectors

Sector Update: Healthcare

Healthcare stocks were mixed Tuesday afternoon, with the NYSE Healthcare Index easing 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) fractionally higher.The iShares Biotechnology ETF (IBB) climbed 1.8%.In corporate news, Merck (MRK) and Pfizer (PFE) raised their respective full-year sales outlooks on Tuesday, as both pharmaceutical giants logged better-than-expected sales for Q2. Merck shares rose 1.2%, and Pfizer added 1.8%.

$MRK$PFE
Merck, Pfizer Lift Full-Year Sales Outlooks Following Second-Quarter Beats
US Markets

Merck, Pfizer Lift Full-Year Sales Outlooks Following Second-Quarter Beats

Merck (MRK) and Pfizer (PFE) raised their respective full-year sales outlooks on Tuesday, as both pharmaceutical giants logged better-than-expected sales for the second quarter.For 2026, Merck now expects revenue of $66.3 billion and $67.3 billion, compared with its prior guidance of $65.8 billion to $67.0 billion and the FactSet-polled consensus of $66.86 billion. The company cut its full-year adjusted earnings estimate to a range of $2.66 and $2.76, from $5.04 to $5.16, to account for charges of $2.43 per share for the acquisition of Terns Pharmaceuticals (TERN). Analysts expect non-GAAP EPS of $2.79.For the June quarter, Merck's sales rose 5% year over year to $16.61 billion, topping the consensus of $16.37 billion. The company swung to a second-quarter non-GAAP loss $0.13 per share due to the Terns acquisition charge, from EPS of $2.13 a year earlier, while analysts expected a loss of $0.27.In May, the company announced completion of the acquisition of Terns and flagged the one-time charge."We delivered growth in the quarter led by continued strength in oncology and animal health, along with increasing contributions from our diverse and compelling new products across an array of therapeutic areas," Merck Chief Financial Officer Caroline Litchfield said at an earnings call, according to a FactSet transcript.Pfizer narrowed its full-year revenue outlook to between $60.5 billion to $62.5 billion from the previous range of $59.5 billion to $62.5 billion, reflecting a $500 million increase at the midpoint. The company maintained its adjusted EPS guidance of $2.80 to $3. At midpoint the estimates are both below the consensus forecasts of $61.77 billion and $2.94, respectively.Pfizer's second-quarter sales grew 3% year over year to $15.03 billion, while analysts projected $14.4 billion. Adjusted EPS fell to $0.77 from $0.78 a year earlier but exceeded the Street's $0.68 forecast."Our launched and acquired products performed well, our obesity program is advancing with meaningful momentum and our oncology portfolio remains a source of strength," Pfizer CEO Albert Bourla said in a statement.Last week, AbbVie (ABBV) lowered its full-year earnings guidance to account for the expected dilution from its planned acquisition of Apogee Therapeutics (APGE), despite reporting stronger-than-expected second-quarter results.Last month, Johnson & Johnson (JNJ) raised its full-year outlook after reporting better-than-expected second-quarter results, driven by growth in its innovative medicine and medical device businesses. Bristol-Myers Squibb (BMY) also raised its full-year guidance after reporting second-quarter results.Merck shares of were advancing by 0.3% in Tuesday morning trade, with the stock up 22% so far this year. Pfizer was down 0.4% intraday and is up about 0.1% since the start of the year.Price: $128.40, Change: $+0.63, Percent Change: +0.49%

$ABBV$APGE$BMY$JNJ$MRK$PFE$TERN
Stocks Rise Pre-Bell Ahead of Latest Round of Earnings; Investors Gauge Uncertainty Over Potential US-Iran Deal
US Markets

Stocks Rise Pre-Bell Ahead of Latest Round of Earnings; Investors Gauge Uncertainty Over Potential US-Iran Deal

US equity futures were tracking in the green on Tuesday as traders await the latest batch of corporate earnings and assess ongoing uncertainty over a potential resolution to the Middle East conflict.The S&P 500 rose 0.2% in premarket activity, while the Dow Jones Industrial Average and the Nasdaq gained 0.3% each. All three main indexes finished Monday trading up, with the Dow notching a record closing high.Caterpillar (CAT), Merck (MRK), McDonald's (MCD), Pfizer (PFE), Spotify Technology (SPOT), Transdigm (TDG), Rockwell Automation (ROK), Archer-Daniels-Midland (ADM), Kimberly-Clark (KMB), BioNTech (BNTX) and DuPont de Nemours (DD) are all scheduled to report their latest financial results before the bell.SpaceX (SPCX) shares were up 2% pre-bell with the rocket and satellite company expected to release its first quarterly results since going public after the markets close, along with Advanced Micro Devices (AMD), Arista Networks (ANET), Amgen (AMGN) and Gilead Sciences (GILD).Palantir Technologies' (PLTR) stock jumped 15% early Tuesday as the company lifted its full-year revenue guidance on the back of stronger-than-expected second-quarter results. Snap (SNAP) climbed 7.3% after the social media company announced second-quarter results above Wall Street's estimates.President Donald Trump reportedly said Monday that the latest round of talks between the US and Iran is the "last chance" for Tehran to "sign a good document." Trump recently called off a planned attack on Iran.However, Iranian Foreign Ministry spokesperson Esmail Baghaei reportedly ruled out an immediate plan to negotiate with Washington. Tehran was in talks with Oman regarding the Strait of Hormuz, the world's most important chokepoint for crude flows, Baghaei reportedly said.West Texas Intermediate crude oil inclined 1.6% to $81.64 a barrel before the opening bell, while Brent advanced 2.3% to $85.66."Hopes of a peace deal in the Middle East weighed on crude prices," D.A. Davidson said in a Monday client note.Treasury yields were trending higher in premarket action, with the two-year rate ticking up 1 basis point to 4.27% and the 10-year rate adding 2.2 basis points to 4.71%.Tuesday's economic calendar has the international trade in goods and services report for June at 8:30 am ET, followed by the Job Openings and Labor Turnover Survey for the same month at 10 am.Gold moved up 0.3% to $4,103 per troy ounce, while bitcoin declined 0.7% to $63,441.

Dow JonesNasdaq CompositeS&P 500$ADM$AMD$AMGN$ANET$BNTX$CAT$DD$GILD$KMB$MCD$MRK$PFE$ROK$SPCX$SPGI$SPOT$TDG
Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index decreasing 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.8%.The iShares Biotechnology ETF (IBB) fell 2.6%.In corporate news, Bausch + Lomb (BLCO) shares fell 2.9%. The company said late Thursday that results from a phase 2 trial assessing BL1107 in people with glaucoma showed the study did not meet its primary endpoint of replicating visual function improvements seen in a smaller phase 1/2a trial.Pfizer's (PFE) Q2 revenue is expected to match Wall Street's estimates, but its EPS may fall short, RBC said in a note. Separately, Pfizer's vaccine disputes with Poland and Romania continue, now extending to the countries' air traffic agencies, Bloomberg reported. Pfizer shares were fractionally higher.SL Science (SLBT) shares gained 4.4% after it said Friday it has submitted an orphan drug designation request to the US Food and Drug Administration for its Gamma Delta T therapy, named Vdelta2+ Gamma Delta T Cells, for the treatment of glioblastoma multiforme.Cosmos Health (COSM) shares jumped 15% after it said Friday that it has launched a subscription-based purchasing model for its consumer health brands.

$BLCO$COSM$PFE$SLBT
Wire

Sector Update: Healthcare Stocks Decline Friday Afternoon

Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding about 1%.The iShares Biotechnology ETF (IBB) fell 2.7%.In corporate news, Bausch + Lomb (BLCO) shares fell 3.5%. The company said late Thursday that results from a phase 2 trial assessing BL1107 in people with glaucoma showed the study did not meet its primary endpoint of replicating visual function improvements seen in a smaller phase 1/2a trial.Pfizer's (PFE) Q2 revenue is expected to match Wall Street's estimates, but its EPS may fall short, RBC said in a note. Separately, Pfizer's (PFE) vaccine disputes with Poland and Romania continue, now extending to the countries' air traffic agencies, Bloomberg reported. Pfizer shares were up 0.1%.Cosmos Health (COSM) shares jumped 10% after it said Friday that it has launched a subscription-based purchasing model for its consumer health brands.

$BLCO$COSM$PFE
Sectors

Sector Update: Healthcare

Healthcare stocks declined Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding about 1%.The iShares Biotechnology ETF (IBB) fell 2.9%.In corporate news, Pfizer's (PFE) Q2 revenue is expected to match Wall Street's estimates, but its EPS may fall short, RBC said in a note. Pfizer shares were fractionally higher.

$PFE
Wire

Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says

Biopharma pricing power will be the key swing factor for Q2 earnings as companies with cleaner growth outlooks continue to outperform peers facing loss-of-exclusivity headwinds, Bank of America said in a note Friday.Merck & Co (MRK), AbbVie (ABBV), Jazz Pharmaceuticals (JAZZ) and Ionis Pharmaceuticals (IONS) remain its top picks.Bank of America raised its price targets on AbbVie to $276 from $234, Johnson & Johnson (JNJ) to $263 from $254 and Eli Lilly to $1,334 from $1,251.The analysts lowered targets on Bristol Myers Squibb (BMY) to $66 from $67, Pfizer (PFE) to $26 from $27 and United Therapeutics (UTHR) to $613 from $620.Price: $123.45, Change: $-1.63, Percent Change: -1.30%

$ABBV$BMY$IONS$JAZZ$JNJ$LLY$MRK$PFE$UTHR
Pfizer Poised for Mixed Second Quarter, RBC Says
US Markets

Pfizer Poised for Mixed Second Quarter, RBC Says

Pfizer's (PFE) second-quarter revenue is expected to match Wall Street's estimates, while its earnings per share may fall short, RBC Capital Markets said in a note on Friday.The brokerage forecasts revenue of $14.43 billion, largely in line with consensus views, with EPS at $0.66, lower than the Street's $0.68 estimate.The drugmaker is scheduled to report its second-quarter financials Aug. 4.Pfizer COVID-19 products Comirnaty and Paxlovid are expected to generate lower-than-expected revenue for the second quarter amid waning demand for vaccinations, RBC analyst Trung Huynh wrote. Prostate cancer drug Xtandi will also likely miss consensus estimates, though Eliquis and Ibrance are seen coming in stronger than expected.Xtandi is co-developed by Pfizer and Astellas Pharma. Eliquis is a blood thinner medicine jointly developed by Bristol Myers Squibb (BMY) and Pfizer, while Ibrance is Pfizer's breast cancer treatment."Our EPS sits 3% below consensus due to unfavorable gross margin mix and elevated (research and development) spending to fund key pipeline programs," according to the RBC note.RBC raised its 2026 revenue forecast to $61.33 billion from $61.25 billion and trimmed the adjusted EPS estimate to $2.86 from $2.90. In May, Pfizer maintained its 2026 guidance, including sales at $59.5 billion to $62.5 billion and earnings of $2.80 to $3 per share."Based on prescription data analysis, we have lower confidence in a (second-quarter) guidance raise and have reduced our 2026 estimates by (1% to 2%), now placing us in the lower half of guidance," Huynh wrote.RBC maintained its sector perform rating on the Pfizer stock, with a $25 price target.Last month, Pfizer named Cecile Guegan interim chief financial officer as Dave Denton prepared to join Nike (NKE) as finance chief. RBC said Pfizer expects to appoint a permanent CFO by the end of 2026.Price: $24.23, Change: $-0.02, Percent Change: -0.10%

$PFE
Wire

BofA Securities Adjusts Pfizer Price Target to $26 From $27

Pfizer (PFE) has an average rating of hold and mean price target of $28.62, according to analysts polled by FactSet.Price: $24.39, Change: $+0.14, Percent Change: +0.56%

$PFE

Showing 1-20 of 63

Track with the FINWIRES app suite

FolioX
FolioX
Track PFE in your portfolio
WheelAI
WheelAI
Analyze PFE options with the wheel strategy
StockInsider
StockInsider
See market sentiment on PFE